Related by context. All words. (Click for frequent words.) 63 cohorts 59 prospective cohort 57 longitudinal study 57 Cohort 56 n = 56 retrospective cohort 55 randomized 55 liver transplant recipients 54 Framingham Offspring Study 54 randomized clinical 54 blind randomized controlled 54 HIV uninfected 54 histologically confirmed 53 retrospective cohort study 53 HCV infected 53 prospectively defined 53 multicenter 53 prospective observational 53 observational cohort study 52 subgroup 52 substudy 51 dose dose escalation 51 logistic regression model 51 longitudinal cohort study 51 multicentre study 51 nulliparous women 51 multicenter randomized controlled 51 randomized controlled trial 51 multicentre 51 null responder HCV 51 multicenter study 51 definite stent thrombosis 51 placebo controlled 50 RRMS patients 50 randomized placebo controlled 50 Prostate Lung Colorectal 50 logistic regression analysis 50 suicide attempters 50 antiretroviral naïve 50 subgroup analyzes 50 multicentre randomized 50 limiting generalizability 50 PARTNER Trial 50 CR nPR 50 Collaborative Perinatal Project 50 prospective multicenter 50 multicentre prospective 50 observational study 50 dosing cohorts 49 normotensive 49 nonrandomized 49 vertebral fracture 49 subanalysis 49 randomized blinded 49 subset 49 Swedish Mammography Cohort 49 tertile 49 histologically proven 49 Kaplan Meier analysis 49 underwent radical prostatectomy 49 aged ≥ 49 biochemical recurrence 49 prospective randomized 49 placebo controlled randomized 49 mg/m2 dose 49 prostate cancer CaP 48 placebo controlled dose escalation 48 viral kinetic 48 Sprague Dawley rats 48 Study ARIC 48 randomized controlled 48 sd = 48 randomized multicenter 48 NSTE ACS 48 dose escalation study 48 placebo controlled clinical 48 genotyped 48 PLCO 48 dosing cohort 48 premenopausal 48 prospectively 48 evaluable subjects 48 ABSORB trial 48 onset atrial fibrillation 48 EDSS score 48 MADIT CRT trial 48 doxorubicin docetaxel 48 dose cohorts 48 IPAH 48 longitudinal studies 48 EDSS scores 48 mg kg dose 48 undetectable HBV DNA 48 baseline HbA1c 48 multicenter prospective 47 genotype 1a 47 ALLHAT 47 prospective multicenter randomized 47 prospectively randomized 47 PreCISe study 47 MADIT II 47 TAXUS V 47 MetS 47 seroconverted 47 multicenter phase 47 nondiabetic 47 retrospectively analyzed 47 evaluable patients 47 blind randomized 47 adenoma recurrence 47 virologic response 47 univariate analyzes 47 prospective observational cohort 47 Baltimore Longitudinal Study 47 cognitively normal 47 NHANES III 47 psychiatric outpatients 47 RESIST studies 47 covariate 47 pharmacokinetics PK 47 Multicenter AIDS 47 Baseline characteristics 47 T2DM 47 TAXUS IV 47 underwent CABG 47 ascending dose 47 multivariate analyzes 47 nondepressed 47 Phase III randomized 47 adjuvant tamoxifen 47 TMC# r 47 randomized multicentre 47 nonobese 47 SORT OUT III 47 osteopenic 47 nonfatal MI 47 dietary questionnaires 47 symptomatic VTE 46 stage IIIB 46 blind randomized placebo 46 Wisconsin Sleep Cohort 46 Atherosclerosis Risk 46 Wistar rats 46 HIV seroconversion 46 % CI #.#-#.# [003] 46 VADT 46 observational cohort 46 post hoc 46 antiretroviral naive 46 multivariable analysis 46 randomized trials 46 MMSE score 46 relapsed AML 46 nomogram 46 Kaplan Meier curve 46 undergoing coronary angiography 46 RCTs 46 visceral metastases 46 CARDIA study 46 dose cohort 46 recurrent VTE 46 lamivudine monotherapy 46 HIV seronegative 46 ± SD 46 hsCRP levels 46 bivariate analyzes 46 retrospective observational study 46 Intervention Trial 46 meta analysis 46 Longitudinal Study 46 Multicenter 46 placebo controlled trials 46 Prospective Investigation 46 prospective randomized multicenter 46 probands 46 conditional logistic regression 46 lowest tertile 46 SIMPADICO 46 CALGB 46 prospective longitudinal 46 double blinded randomized 46 PCa 46 prospective nonrandomized 46 evaluable 46 nonpsychotic 46 MADRS score 46 comorbidity 46 neoadjuvant 46 CARDIA 46 virologic failure 46 HORIZONS AMI trial 46 NNRTI resistance 45 locoregional recurrence 45 treatment naļve 45 advanced neoplasia 45 Carotid Revascularization Endarterectomy vs. 45 double blind placebo 45 pCR 45 randomized multicenter trial 45 relapsed MM 45 prospective randomized controlled 45 unblinded 45 ROCKET AF 45 Cohort Study MACS 45 Framingham Offspring 45 RE LY ® 45 HCV SPRINT 45 % CI #.#-#.# [002] 45 familial aggregation 45 single ascending dose 45 placebo controlled Phase III 45 multicenter randomized 45 subpopulation 45 seronegative 45 liver histology 45 univariate analysis 45 dose escalation Phase 45 hip BMD 45 P = .# 45 TT genotype 45 underwent liver transplantation 45 covariates 45 telomere lengths 45 morphometric vertebral fractures 45 nondemented 45 completers 45 T2 lesions 45 everolimus eluting stents 45 CC genotype 45 femoral neck BMD 45 DCCT 45 Prostate Cancer Prevention 45 androgen deprivation 45 postintervention 45 proband 45 achieved sustained virological 45 colorectal neoplasia 45 placebo controlled studies 45 randomly assigned 45 systolic dysfunction 45 serum PSA 45 nonvertebral fractures 45 depressive symptoms 45 genotypic resistance 45 lipid lowering therapy 45 mg BID 45 randomized #:# 45 multivariate analysis 45 randomized controlled clinical 45 neoadjuvant chemotherapy 45 HF ACTION 45 % CI #.#-#.# [006] 45 adjuvant therapy 45 biochemical relapse 45 virological failure 45 randomized Phase III 45 contralateral breast cancer 45 median PFS 45 composite endpoint 45 singleton pregnancies 45 multicenter randomized double 45 DAS# scores 45 nonoperative treatment 45 pegylated interferon alfa 2b 45 nonsignificant difference 45 Multiethnic Cohort Study 45 Osteoporotic Fractures 44 Randomized 44 NHANES 44 prostate cancer PCa 44 Normative Aging Study 44 efficacy endpoint 44 efficacy evaluable 44 subclinical hypothyroidism 44 subtrochanteric 44 prespecified 44 HbA1c levels 44 WHEL 44 RECIST criteria 44 HBeAg positive 44 multicenter clinical 44 UKPDS 44 HIV HCV coinfected 44 #mg QD [002] 44 chemoradiotherapy 44 highest quintile 44 opioid dependent 44 mg dose 44 HYVET 44 de novo AML 44 macroalbuminuria 44 pharmacodynamics PD 44 antiretroviral regimen 44 multivariable Cox 44 extensive metabolizers 44 METHODS 44 underwent resection 44 baseline A1C 44 FAME Study 44 RE LY 44 double blinded placebo 44 NIH CPSI 44 hepatic resection 44 tertiles 44 quartiles 44 BRCA mutation carriers 44 prospective multicentre 44 NHANES surveys 44 AIM HIGH 44 randomized crossover 44 randomizing patients 44 Free Survival PFS 44 undergoing radical prostatectomy 44 Millennium Cohort Study 44 VLBW infants 44 TMC# C# 44 landmark ATHENA 44 AIR CF3 44 chemotherapy regimen 44 Subgroup analysis 44 Kruskal Wallis test 44 heavily pretreated patients 44 Cohort Study 44 nab paclitaxel 44 LEXIVA r 44 subgroups 44 timepoint 44 beta blocker therapy 44 multiple logistic regression 44 tipranavir r 44 Trial ASCOT 44 cystectomy 44 antidepressant therapy 44 Birth Cohort 44 Nutrition EPIC 44 Phase 2b study 44 ischemic cardiomyopathy 44 Subgroup analyzes 44 Univariate analysis 44 serum samples 44 placebo controlled clinical trials 44 lymphocytosis 44 % CI #.#-#.# [007] 44 habitual snoring 44 atopic 44 hepatectomy 44 Alzheimer Disease Neuroimaging Initiative 44 non squamous histology 44 HSCT 44 psychiatric morbidity 44 PSADT 44 genotype 1b 44 operable breast cancer 44 vicriviroc 44 preoperative PSA 44 EURIDIS 44 multicentre randomized double 44 paclitaxel eluting stents 44 cardiovascular mortality 44 RE LY trial 44 serum lipid levels 44 mITT population 44 SYNTAX 44 PREVENT IV 44 baseline CD4 44 enrolled 44 prepubertal 44 GH deficiency 44 Index CDAI 44 adjuvant chemotherapy 44 preserved LVEF 44 Operative mortality 44 CYPHER Stent 44 MACCE 44 SCD HeFT 44 elevated CRP 43 MMSE scores 43 renal tumors 43 dose escalation trial 43 metaanalysis 43 experienced virologic failure 43 sustained virological response 43 heavily pretreated 43 kidney transplant recipients 43 androgen suppression 43 mg kg cohorts 43 confounding variables 43 eplerenone 43 fragility fractures 43 liver biopsies 43 Randomized controlled 43 recurrent GBM 43 affective disorder 43 highest tertile 43 coronary revascularization 43 FDG PET scans 43 hemoglobin concentration 43 5-FU/LV 43 paroxysmal AF 43 trials RCTs 43 serum testosterone 43 metastatic HRPC 43 darunavir ritonavir 43 adenoma 43 NSTEMI 43 periprocedural MI 43 advanced adenomas 43 ascending doses 43 melphalan prednisone 43 CAMMS# 43 virologic response EVR 43 ng mL 43 undergone radical prostatectomy 43 nulliparous 43 conjugated equine estrogen 43 multivariate logistic regression 43 locoregional 43 DMIST 43 mCRC patients 43 completely resected 43 FDA defined valvulopathy 43 thromboembolic complications 43 TAXUS Express Stent 43 myocardial infarctions MI 43 NO# [002] 43 controlled multicenter 43 NRTI 43 Health Initiative Observational 43 URTI 43 efavirenz EFV 43 APTIVUS r 43 National Birth Cohort 43 multicenter trials 43 attain statistical significance 43 longitudinal observational study 43 NMIBC 43 drank pomegranate juice 43 recurrent endometrial cancer 43 onset AF 43 lowest quintile 43 GH deficient 43 MIs 43 T1c 43 Phase Ib clinical 43 Multi Ethnic Study 43 CLBP 43 STEP BD 43 HCV genotype 43 Netherlands Cohort Study 43 Communities ARIC study 43 abnormal cytology 43 meta regression 43 psychiatric comorbidities 43 mcg albinterferon alfa 2b 43 fragility fracture 43 NATRECOR ® 43 BMD measurements 43 ziprasidone 43 relapsers 43 safety tolerability pharmacokinetics 43 prospectively evaluated 43 multiple ascending dose 43 serum creatinine levels 43 univariate 43 quintiles 43 HCV genotype 1 43 prognostic variables 43 KRAS mutations occur 43 euthyroid 43 prevalent vertebral fracture 43 VcMP 43 Phase Ib IIa clinical 43 study 43 secondary efficacy endpoint 43 null responder 43 ug dose 43 ELBW infants 43 logistic regression models 43 kidney allograft 43 pre menopausal 43 CTEPH 43 atazanavir ritonavir 43 blinded randomized placebo controlled 43 BARI 2D 43 blind multicenter 43 Logistic regression 43 thyroidectomy 43 SYNTAX trial 43 ERSPC 43 Ovarian PLCO Cancer 43 LVEF 43 AIR CF1 43 dose escalation clinical 43 postdischarge 43 clinical trial 43 hippocampal volume 43 lymphoproliferative disorder 43 HBeAg negative chronic hepatitis 43 serum GGT 43 germline mutations 43 genotype 43 preoperative chemotherapy 43 statin therapy 43 label dose escalation 43 bivariate 43 carotid stenosis 43 cells mcL 43 prevalences 43 atheroma volume 43 randomized double 43 depressive episode 43 irbesartan 43 ECG abnormalities 43 blinded placebo controlled 43 DAPT 42 randomized Phase IIb 42 virological response 42 extracapsular extension 42 cirrhotic 42 pretransplant 42 multicenter Phase II 42 hippocampal volumes 42 DSM IV diagnosis 42 warfarin therapy 42 TAXUS VI 42 eGFR 42 nonmetastatic prostate cancer 42 seminal vesicle invasion 42 receiving VICTRELIS 42 mITT 42 histologically 42 prognostic factors 42 serum vitamin D 42 confidence interval CI 42 randomized #:#:# 42 Hb A1C 42 Phase 2b trial 42 dose escalation 42 mcg linaclotide 42 PSA nadir 42 systolic blood pressure 42 multicenter randomized placebo controlled 42 T1DM 42 dose regimen 42 allele frequencies 42 randomized controlled trials 42 syndromal 42 estimated GFR 42 Ovarian Cancer Screening 42 unipolar depression 42 carboplatin paclitaxel 42 unmedicated 42 pre pubertal 42 conducted retrospective cohort 42 breast carcinoma 42 elective percutaneous coronary 42 Phase III randomized controlled 42 nonpregnant 42 colorectal cancer incidence 42 free survival PFS 42 CD4 cell 42 ANCOVA 42 posttransplant 42 cerebral artery occlusion 42 pg ml 42 phase IIIb 42 tumor shrinkage 42 perioperative complications 42 confounder 42 BMI z 42 CORE OM 42 microalbuminuria 42 phase Ib 42 postmenopausal 42 serum estradiol 42 CVD mortality 42 lymphocyte count 42 XIENCE V PROMUS Stent 42 potent antiretroviral therapy 42 APEX AMI trial 42 patientswith 42 QTc 42 intravenous diuretics 42 BMI percentile 42 CaP 42 dose regimens 42 onset diabetes mellitus 42 paclitaxel carboplatin 42 randomization 42 HNSCC 42 Stage IIIb 42 posttreatment 42 phase IIa 42 unselected 42 nonexposed 42 microbiologically evaluable 42 incomplete revascularization 42 metastatic malignant melanoma 42 LV dysfunction 42 Acute Decompensated Heart Failure 42 nonfatal myocardial infarction 42 Partial Responses 42 elevated troponin 42 ILLUSTRATE 42 relapsed GBM 42 glycated hemoglobin HbA1c 42 blind placebo controlled 42 Coronary Artery Risk 42 dose escalation phase 42 schizotypal traits 42 intravascular ultrasonography 42 EMPHASIS HF trial 42 plasma folate 42 systolic BP 42 hepatitis C genotype 42 noninferiority 42 CHAMPION PCI 42 patients undergoing CABG 42 HBeAg negative 42 tumor histology 42 euthymic patients 42 BRCA2 mutation carriers 42 arteriography 42 ipsilateral stroke 42 Edge STudy 42 doxorubicin cyclophosphamide 42 RTOG 42 neurodevelopmental impairment 42 follicular NHL 42 HbA 1c 42 mcg dose 42 multivariable logistic regression 42 underwent bariatric surgery 42 subcutaneous doses 42 carotid artery narrowing 42 prostate cancer CRPC 42 events SAEs 42 VTE 42 coronary calcification 42 nucleoside naive 42 phase IIb study 42 Phase 1b 42 comorbidities 42 lopinavir r 42 femoral neck fracture 42 TG MV 42 MELD scores 42 sociodemographic variables 42 serum IGF 42 quintile 42 #.#ng/ml 42 Kaplan Meier curves 42 nonfasting triglyceride levels 42 esophagectomy 42 multivariate Cox 42 pharmacodynamic effects 42 EchoCRT 42 undergoing CABG 42 sociodemographic characteristics 42 squamous histology 42 Median survival 42 CD4 + cell 42 confidence interval #.#-#.# 42 HbA1C levels 42 prospectively enrolled 42 remission CR 42 lymphoproliferative 42 MVax R 42 nondiabetic patients 42 castration resistant prostate cancer 42 atherothrombotic disease 42 confounders 42 low dose cytarabine 42 undergoing bariatric surgery 42 atrioventricular block 42 carotid plaques 42 XELOX 42 hydroxyvitamin D levels 42 timepoints 42 clinicopathological 42 SCr 42 adalimumab 42 waist circumferences 42 HGPIN 42 Phase IIIb study 42 BR.# 42 asymptomatic metastatic 42 CR CRu 42 Phase IIa trial 42 TIMI 42 phase IIb clinical 42 melanocytic nevi 42 epithelial ovarian cancer 42 gadolinium enhanced 42 EVEREST II 42 CIN3 42 distal radial fractures 42 knee arthroplasty 42 hemodialysis patients 42 RSD# oral 42 dysthymia 42 Phase IIIb clinical 42 myocardial infarctions 42 acetabular fracture 42 Avon Longitudinal Study 42 asymptomatic PAD 42 hip fracture 42 clinicopathological features 42 sociodemographic factors 42 MEND CABG 42 % Confidence Interval 42 cART 42 GIK infusion 42 PRECiSE 42 myocardial infarction MI 41 peginterferon alfa 2a 41 ABSSSI 41 Polyp Prevention Trial 41 ELCAP 41 REYATAZ r arm 41 fasting triglyceride levels 41 chest radiograph 41 risperidone olanzapine 41 Caucasian males 41 adiponectin concentrations 41 Mania Rating Scale 41 randomized multicenter Phase III 41 mcg BID 41 SNP rs# [002] 41 NIHSS score 41 Phase 1b trial 41 immunosuppressive regimen 41 ANDROMEDA 41 interquartile range 41 certolizumab 41 advanced adenoma 41 sustained virologic response 41 Cohorts 41 partial nephrectomy 41 Flu Cy 41 subclinical atherosclerosis 41 mCRPC 41 cirrhotic patients 41 imatinib therapy 41 placebo controlled Phase 41 ritonavir boosted 41 HeFT 41 randomized Phase 2b 41 coinfected patients 41 logistic regression analyzes 41 XIENCE V demonstrated 41 Vicor PD2i Cardiac Analyzer 41 tirofiban 41 periprocedural 41 relapsed myeloma 41 virologic 41 LVSD 41 Atherosclerosis MESA 41 treatment naive genotype 41 nonadherent 41 chest radiographs 41 oral prednisolone 41 adjunctive placebo 41 postoperative mortality 41 odds ratios ORs 41 stage IIIb IV 41 blind placebo 41 dyads 41 ECOG 41 hypercholesterolemic 41 inhaled tobramycin 41 chronicity 41 colorectal adenoma 41 plasma pharmacokinetics 41 mg/m2 cohort 41 antibody titer 41 multicenter randomized clinical 41 nephron sparing surgery 41 recurrent glioblastoma multiforme 41 Kay Tee Khaw 41 phase IIb 41 Feasibility Trial 41 Exclusion criteria 41 DLTs 41 chronic periodontitis 41 chemoradiation 41 nonresponders 41 pharmacokinetic PK 41 lacunar 41 genotypes 41 stage IIIb 41 postoperative complication 41 nephrectomy 41 NSABP B 41 radical prostatectomy 41 TKAs 41 relapsing remitting 41 median CD4 41 ALLEGRO 41 CATIE AD 41 radical nephrectomy 41 multicenter placebo controlled 41 MEND CABG II 41 mg BID dose 41 postmenopausal women 41 prospective randomized placebo 41 hypertensives 41 #mg BID [002] 41 angiographically 41 statistically nonsignificant 41 liver metastases 41 Phase IIIb 41 patients evaluable 41 MADIT CRT 41 elevated LDL cholesterol 41 insulin detemir 41 IV NSCLC 41 graft dysfunction 41 HPTN 41 locoregional disease 41 PFO migraine 41 recurrent venous thromboembolism 41 estimated glomerular filtration 41 BMI ≥ 41 AVADO 41 elevated serum creatinine 41 ≥ 41 MADIT 41 clinico pathological 41 acute myelogenous leukemia AML 41 VITAL Trial 41 % CI #.#-#.# [008] 41 IDH1 mutation 41 cytogenetic response 41 radical prostatectomy RP 41 prostate carcinoma 41 5-fluorouracil/leucovorin 41 pegylated liposomal doxorubicin 41 CI #.#-#.# [001] 41 GYTS 41 ACR Pedi 41 lamivudine refractory patients 41 plasma uric acid 41 endoscopic remission 41 pheochromocytoma 41 COU AA 41 Phase 2a trial 41 Clinical Antipsychotic Trials 41 Scandinavian Cardiac Outcomes 41 p = .# [002] 41 psychiatric comorbidity 41 knee OA 41 affective psychosis 41 methotrexate monotherapy 41 Complications Trial DCCT 41 lymphadenectomy 41 sirolimus eluting stents 41 SCIg 41 clinically localized prostate 41 metastatic RCC 41 RBC folate 41 glycated hemoglobin levels 41 mcg doses 41 specific antigen PSA 41 GISSI HF 41 subsample 41 strongest predictor 41 blinded randomized controlled 41 ST elevation myocardial 41 MIST II 41 dosage regimens 41 bacterial prostatitis 41 EMPHASIS HF 41 ENDEAVOR clinical 41 Thrombolysis 41 dyslipidaemia 41 SWOG 41 % CI #.#-#.# [004] 41 retrospective observational 41 receiving highly emetogenic 41 rFSH 41 seroprevalence 41 serum creatinine 41 ECASS 41 Nutrition Examination Survey NHANES 41 retrospectively reviewed 41 axillary node dissection 41 clinically meaningful improvement 41 ConclusionThis 41 hemodynamically significant 41 symptomatic intracerebral hemorrhage 41 postoperative chemotherapy 41 Acetonide 41 Randomised 41 dysglycemia 41 rapid virologic response 41 baseline LDH 41 serum PTH 41 HAM D# scores 41 weekly subcutaneous injections 41 thrombolytic therapy 41 Primary endpoints 41 solifenacin 41 seropositivity 41 COPD exacerbation 41 p = #.# [002] 41 developmental dysplasia 41 Dose escalation 41 ELBW 41 label multicenter 41 inbreeding coefficient 41 response pCR 41 CHAMPION PLATFORM 41 cryptogenic stroke 41 ECOG PS 41 ADHF 41 Kaplan Meier method 41 acute leukemias 41 pomalidomide 41 CCR5 tropic HIV 41 histologies 41 spirometric 41 homocysteine concentrations 41 p = #.# [003] 41 DMARD 41 total hip arthroplasty 41 MIRP 41 YPDP 41 perioperatively 41 previously untreated follicular 41 immunocompetent 41 T2D 41 DMARD therapy 41 Twin Registry 41 authors conclude 41 lipid lowering medications 41 ascending dose study 41 IL#B 41 controlled dose escalation 41 parous 41 #mg/m# [001] 41 mildly symptomatic 41 coronary angiograms 41 HER2 positive cancers 40 nonsignificant 40 adjuvant tamoxifen therapy 40 CSBM 40 secondary endpoint 40 ear effusion 40 hypogonadal 40 hematopoietic cancers 40 ENGAGE AF TIMI 40 PCPT 40 radical cystectomy 40 elevated ALT 40 transrectal ultrasound guided 40 ADHD RS 40 recidivate 40 OLYMPIA registry 40 ragweed allergic 40 ovariectomized 40 genomewide association studies 40 abstainers 40 MERLIN TIMI 40 inhaled corticosteroid therapy 40 acid suppressive medications 40 Young Adults CARDIA 40 LHRH receptor positive 40 pneumonectomy 40 randomisation 40 sociodemographic 40 ng ml 40 ACCOMPLISH 40 symptomatic BPH 40 phase IIa clinical 40 progression TTP 40 Randomized trials 40 fasting glucose levels 40 EINSTEIN DVT 40 Sarano 40 randomized controlled trials RCTs 40 dietary glycemic index 40 PLCO trial 40 Randomized Evaluation 40 operable pancreatic cancer 40 suboptimal adherence 40 Screening Trial 40 Multivariate analyzes 40 refractory CLL 40 Phase 1b clinical 40 elotuzumab 40 AIR2 Trial 40 pooled comparator 40 REVIVE Diabetes 40 Multicenter Automatic Defibrillator Implantation 40 TEAEs 40 dataset 40 debulking surgery 40 peptic ulcer bleeding